Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit.

[1]  P. Lam,et al.  Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[2]  Angela Smallwood,et al.  Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2007, Journal of medicinal chemistry.

[3]  P. Lam,et al.  Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. , 2007, Bioorganic & medicinal chemistry letters.

[4]  D. Kubitza,et al.  Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. , 2007, Hamostaseologie.

[5]  Q. Ma.  Development of oral anticoagulants. , 2007, British journal of clinical pharmacology.

[6]  Chong-Hwan Chang,et al.  SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa. , 2007, Bioorganic & medicinal chemistry letters.

[7]  V. Laux,et al.  Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. , 2007, Seminars in thrombosis and hemostasis.

[8]  E. Zhang,et al.  Structure‐based Drug Design of Pyrrolidine‐1, 2‐dicarboxamides as a Novel Series of Orally Bioavailable Factor Xa Inhibitors , 2007, Chemical biology & drug design.

[9]  A. Turpie.  Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  A. Spyropoulos.  Investigational treatments of venous thromboembolism , 2007, Expert opinion on investigational drugs.

[11]  J. Weitz,et al.  Beyond heparin and warfarin: the new generation of anticoagulants , 2007, Expert opinion on investigational drugs.

[12]  S. Schellong,et al.  New anticoagulants , 2007, Hämostaseologie.

[13]  A. Casimiro-Garcia,et al.  A Versatile Copper-Catalyzed Coupling Reaction of Pyridin-2(1H)-ones with Aryl Halides. , 2006 .

[14]  D. Kubitza,et al.  Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases , 2006, Expert opinion on investigational drugs.

[15]  J. Weitz,et al.  The status of new anticoagulants , 2006, British journal of haematology.

[16]  A. Casimiro-Garcia,et al.  Progress in the discovery of Factor Xa inhibitors , 2006 .

[17]  Thomas Lampe,et al.  Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. , 2005, Journal of medicinal chemistry.

[18]  A. Hinton,et al.  Ximelagatran: a clinical perspective. , 2005, European journal of internal medicine.

[19]  François Diederich,et al.  Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. , 2005, Angewandte Chemie.

[20]  Hans Matter,et al.  Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. , 2005, Journal of medicinal chemistry.

[21]  Hans Matter,et al.  Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. , 2005, Journal of medicinal chemistry.

[22]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[23]  B. Eriksson.  Clinical Experience with Ximelagatran in Orthopaedic Surgery , 2004, Drugs.

[24]  M. Crowther,et al.  Ximelagatran: the first oral direct thrombin inhibitor , 2004, Expert opinion on investigational drugs.

[25]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[26]  Sébastien Maignan,et al.  Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. , 2003, Journal of medicinal chemistry.

[27]  Bin Ye,et al.  Crystal structures of two potent nonamidine inhibitors bound to factor Xa. , 2002, Biochemistry.

[28]  W. Bode,et al.  Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants , 1997, The EMBO journal.

[29]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[30]  S. Schaus,et al.  Practical Synthesis of Enantiopure Cyclic 1,2-Amino Alcohols via Catalytic Asymmetric Ring Opening of Meso Epoxides , 1997 .

[31]  J. Hirsh,et al.  Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.

[32]  Wolfgang Kabsch,et al.  Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants , 1993 .

[33]  L Goldman,et al.  Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. , 1989, The American journal of medicine.

[34]  P. D. Di Cesare,et al.  Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives. , 1989, Journal of medicinal chemistry.

[35]  T W Meade,et al.  Haemostasis and thrombosis. , 1978, International journal of epidemiology.

[36]  Fred. Einberg.  Alkylation of 5-substituted tetrazoles with .alpha.-chlorocarbonyl compounds , 1970 .

[37]  G. Escolar,et al.  Rivaroxaban : Factor Xa inhibitor prop INN anticoagulant , 2006 .

[38]  L. Sorbera,et al.  Dabigatran/dabigatran etexilate : Pevention of DVT prevention of ischemic stroke thrombin inhibitor , 2005 .

[39]  C. White,et al.  Ximelagatran: A new oral anticoagulant , 2004 .

[40]  R. Colman,et al.  Hemostasis and Thrombosis: Basic Principles and Clinical Practice , 1988 .